Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet® and AmBisome® in combination with caspofungin to rats infected with Aspergillus fumigatus
- 1 July 2007
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 96 (7) , 1737-1747
- https://doi.org/10.1002/jps.20801
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- New antifungal drugs and new clinical trialsCurrent Opinion in Oncology, 2003
- Combination therapy with caspofungin and liposomal amphotericin B for invasive aspergillosisThe Pediatric Infectious Disease Journal, 2003
- Refractory Aspergillus pneumonia in patients with acute leukemiaCancer, 2003
- In Vitro Synergy of Caspofungin and Amphotericin B against Aspergillus and Fusarium sppAntimicrobial Agents and Chemotherapy, 2002
- Amphotericin B colloidal dispersion: an improved antifungal therapyAdvanced Drug Delivery Reviews, 2001
- Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studiesAntimicrobial Agents and Chemotherapy, 1997
- Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of ratsAntimicrobial Agents and Chemotherapy, 1997
- Pharmacokinetics and Toxicity of Continuous Infusion Amphotericin B in Cancer PatientsJournal of Pharmaceutical Sciences, 1989
- Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicinCancer Chemotherapy and Pharmacology, 1989
- Infection in cancer patients: A continuing associationThe American Journal of Medicine, 1986